What is Gene Therapy Program | University of Pennsylvania's phone number?

You can contact Gene Therapy Program | University of Pennsylvania's main corporate office by phone at +1-215-573-****.

What is Gene Therapy Program | University of Pennsylvania's official website and social media links?

Gene Therapy Program | University of Pennsylvania's official website is upenn.edu. Gene Therapy Program | University of Pennsylvania has social profiles on LinkedIn.

How much revenue does Gene Therapy Program | University of Pennsylvania generate?

Gene Therapy Program | University of Pennsylvania's annual revenue is estimated to be $10M - $25M.

How many employees does Gene Therapy Program | University of Pennsylvania have currently?

Gene Therapy Program | University of Pennsylvania has approximately 25 employees.

What industry does Gene Therapy Program | University of Pennsylvania belong to?

Gene Therapy Program | University of Pennsylvania operates in the Biotechnology Research industry.

What technology does Gene Therapy Program | University of Pennsylvania use?

Gene Therapy Program | University of Pennsylvania's tech stack includes Android, HTML5 Mobile Boilerplate, XML, LexisNexis, Mailchimp.

What is Gene Therapy Program | University of Pennsylvania's NAICS code?

Gene Therapy Program | University of Pennsylvania's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Gene Therapy Program \| University of Pennsylvania Email Formats	Example	Percentage
FLast@upenn.edu	JDoe@upenn.edu	82%
FirstL@upenn.edu	JohnD@upenn.edu	8%
Last@upenn.edu	Doe@upenn.edu	5%
LastF@upenn.edu	DoeJ@upenn.edu	5%

Gene Therapy Program | University of Pennsylvania

Q: When was Gene Therapy Program | University of Pennsylvania founded?

Gene Therapy Program | University of Pennsylvania was founded in 1993.

Biotechnology ResearchPennsylvania, United States11-50 Employees

The Gene Therapy Program at the University of Pennsylvania is a biotechnology research initiative focused on discovering and translating gene therapy approaches, with an emphasis on developing next-generation gene transfer vectors and applying them to a range of inherited and acquired diseases. Led by Dr. James Wilson, the program has contributed to advancing gene transfer technology toward clinical use, evidenced by a substantial body of publications and patent activity. Located in Philadelphia, Pennsylvania, the program operates within the university's research ecosystem and has drawn support from a diverse mix of public and private sponsors.

On October 1, 2024, the Gene Therapy Program transitioned its activities to Gemma Biotherapeutics (GEMMABio) and Franklin Biolabs. Its overarching objective is to develop and commercialize genetic-based therapeutics aimed at addressing the unmet needs of patients with inherited genetic diseases.

Insights

Similar companies to Gene Therapy Program | University of Pennsylvania

Orchard Therapeutics - U.S.

AVROBIO

GenSight Biologics

Editas Medicine

uniQure

bluebird bio

OXB